About the Partners

The International Cancer Research Partnership (ICRP) is a unique alliance of cancer research organizations from Australia, Canada, France, Japan, the Netherlands, United Kingdom, and the United States. The Partners share funding information to enhance global collaboration and strategic coordination of research between individual researchers and organizations.

Learn More About...

Our Partners

ICRP partners represent a wide range of governmental, public and non-profit cancer research funding organizations from across the world.

Our Leadership

Chair

Naba Bora, PhD (Congressionally Directed Medical Research Programs (CDMRP), U.S. Dept. of Defense)

Vice-Chair

Paul Jackson, PhD (Cancer Australia)

Website & Database Committee

Chair: Laura Prakash, MPH (NCI Center for Global Health, USA)

Finance Committee

Chair: Kimberly Badovinac, MA, MBA (Canadian Cancer Research Alliance)

Annual Meeting 2021 Meeting Committee

[In person meetings on-hold due to COVID-19]

Operations Committee

Chair: Marion Kavanaugh-Lynch, PhD (California Breast Cancer Research Program, USA)

Communications and Membership Committee

Chair: Doug Perin, MPH, JD (NCI Center for Global Health, USA)
Vice-Chair: Paul Jackson, PhD (Cancer Australia)

Data Quality and Analysis Committee

Chair: Kimberly Badovinac, MA, MBA (Canadian Cancer Research Alliance)
Vice-Chair: Karima Bourougaa, PhD (Institut National du Cancer, France)

Evaluations Committee

Chair: Kari Wojtanik, PhD (Susan G. Komen for the Cure)

Operations Manager

Lynne Davies, PhD

Our Partner Representatives

Each partner organization designates one or more person as an official contact for the ICRP and these individuals are listed below (in alphabetical order by country, organization and representative). Multiple staff members from organizations are welcome to participate in ICRP events, activities and projects.

Australia	Representatives
Cancer Australia	Paul Jackson, PhD
Cancer Institute New South Wales	Emma Heeley, PhD
National Breast Cancer Foundation	Chris Pettigrew, PhD
Belgium	Representatives
Anticancer Fund	Gauthier Bouche, PhD
Canada	Representatives
Canadian Cancer Research Alliance (CCRA) Representing 42 Canadian cancer organizations	Kim Badovinac, MA, MBA
France	Representatives
Fondation ARC	Sandrine Duboeuf, PhD Gwendoline Depiedou, PhD
French National Cancer Institute / Institut National du Cancer (INCa)	Karima Bourougaa, PhD Carla Estaquio, PhD
International	Representatives
World Cancer Research Fund International	Giota Mitrou, PhD Anna Diaz Font, PhD
Italy	Representatives
Fondazione AIRC	Laura Galbiati, PhD
Japan	Representatives
AMED Japan	Yuki Sato, PhD
Netherlands	Representatives
Dutch Cancer Society / Kankerbestrijding (KWF)	Linda Kroeskop-Bossenbroek, PhD Annemarie Weerman, PhD
Spain	Representatives
Asociación Española Contra el Cáncer (AECC) (Spanish Association Against Cancer)	Marta Puyol Escolar, PhD
UK	Representatives
National Cancer Research Institute (NCRI) Representing over 20 UK funders	Ian Lewis, PhD Abdul Mutabbir
Worldwide Cancer Research	Helen Rippon, PhD Lynn Turner, PhD
USA	Representatives
American Institute for Cancer Research (AICR)	Nigel Brockton, PhD
American Cancer Society (ACS)	Linda Kee, PhD
American Society for Radiation Oncology (ASTRO)	Sabrina Joseph, PhD
California Breast Cancer Research Program (CBCRP)	Nick Anthis, PhD Mhel Kavanaugh-Lynch, MD, MPH Katie McKenzie, PhD Senaida Poole, PhD
Coalition Against Childhood Cancer (CAC2) – representing over 20 funding organizations	Amy J. Weinstein (National Director, PBTF)
Congressionally Directed Medical Research Programs (CDMRP), U.S. Dept. of Defense	Naba Bora, PhD
National Cancer Institute (NCI) - Center for Research Strategy	Michelle Bennett, PhD Melissa Antman, PhD Laura Brockway Lunardi, PhD
National Cancer Institute (NCI) / DEA/RAEB	Marilyn Gaston Ed Kyle Beth Buschling
National Cancer Institute (NCI) - Center for Global Health	Kalina Duncan, PhD Douglas Puricelli Perin, MPH, JD (Leidos Biomedical Research, Inc.) Laura Prakash, PhD
Oncology Nursing Society Foundation (ONS)	Anizia Karmazyn (Executive Director) Aly Kocon (Foundation Programs Coordinator)
Pancreatic Cancer Action Network (Pancan)	Donna Manross, BS Maya Bader, PhD
Radiation Oncology Institute	Emily Connelly, PhD
Susan G. Komen® (Komen)	Stephanie Birkey-Reffey, PhD Kari Wojtanik, PhD Jerome Jourquin, PhD

Single-funder organizations
Partner	Caveat
ACS	Dollar amounts found in the ICRP database are different than what is reported in the American Cancer Society\'s Annual Report. This is because the annual report has been audited. The dollar amounts spent on research reported in this document includes operating expenses of the Research Department. Additionally, the dollar amounts also exclude all grants that were cancelled after being awarded, but includes money that was returned from grants cancelled in the current year that were awarded in previous years. The dollar amounts reported in the database are unaudited and include grants awarded each fiscal year, exclusive of grants that cancelled before activation.
CBCRP	The California Breast Cancer Research Program grants are awarded only to individuals or institutions in California. Grants to the University of California receive only direct funds, while grants to other institutions also receive indirect costs (overhead) at 25% or the federally negotiated rate. Collaborative awards are counted in graphs and tables by the number of co-Principal Investigators rather than the number of projects.
Komen	Dollar amounts found in the ICRP database are different than what is reported on Komen\'s website or in Komen\'s Annual Report for the following reasons: Komen commits all funds necessary to support a research grant in the year it is awarded. Therefore, Komen\'s website reports on the full amount of each grant in the year it is initiated, while the ICRP data is annualized, as described. Komen funds research grants to our Scientific Advisors (Scientific Advisory Board members and Komen Scholars) and also provides discretionary funding of research-related projects that are not traditional research grants (e.g. support of the Komen Tissue Bank, ASCO and AACR meeting support). These are included in the overall Research Program spending, as reported in our Annual Report and on our website, but are not included in the ICRP database.
NIH	NIH projects in NIH Reporter assigned to the Spend Category ‘cancer’ are included in the ICRP database from FY2005 onwards. A small number of projects are excluded if essential information is missing (primarily Project title, Institution). Previous years’ data were drawn from the NFRP and may be incomplete. Starting in FY2007 NCI reports funding supplements, etc., for each grant separately instead of including them in the main project, therefore the number of projects may differ significantly from those of previous years. Projects with a cost of $0 include those that were a no-cost extension of the grant or when funding was provided by another NIH institute or center for that FY. NCI dollars in the ICRP database are drawn from NIH reporter and may not match dollars from other NCI-only databases.
Worldwide Cancer Research	Worldwide Cancer Research is unique in that the majority of our funding is awarded to researchers in countries outside the UK. Like many UK research charities, Worldwide Cancer Research only funds the direct costs of research. This creates significant problems in making quantitative comparisons between our funding and that provided by some of the other agencies in the ICRP, which fund both the direct and indirect costs (often called overheads) of research.

UK Organizations that are part of NCRI
Partner	Caveat
NCRI (GENERIC)	"NCRI submits data to ICRP on behalf of all UK NCRI members from its Cancer Research Database (CaRD). The database only includes entries where funding can be directly attributed to a set of clearly defined research objectives. This means that the CaRD only contains information on all direct research funding (project, programme, fellowship, unit and institute) financed by NCRI Member organizations, for which an abstract has been submitted and where the project is active on 1 April in any given year. Examples of funding that are currently outside the scope of CaRD are infrastructure, meeting grants and research management support."
Breakthrough (UK)	The ICRP database includes all Breakthrough Breast Cancer\'s research spend reported through its Annual Reports & Accounts. There is some variance due to different reporting periods (1 April snapshot versus full financial year) meaning that some research spend that is already committed may not be included in the ICRP figures. Expenditure on non-research charitable activities and management support costs are excluded from the NCRI, and by extension, the ICRP dataset. For further information on Breakthrough\'s research please visit www.breakthroughresearch.org.uk or email research@breakthrough.org.uk
CR-UK (UK)	The ICRP database includes around 70% of Cancer Research UK\'s direct research spend per financial year as reported through its Annual Reports & Accounts. There is some variance due to different reporting periods (1 April snapshot versus full financial year) meaning that some direct research spend that is planned for allocation will not be included in the ICRP figures. Expenditure on vital research services, technology transfer, meeting grants, research management support and infrastructure to support Cancer Research UK\'s activities is excluded from the NCRI, and by extension, the ICRP dataset.
Department of Health (UK)	There will always be some variance between the figures available on ICRP and the figures reported publicly by DH. There are two reasons for this. Firstly, there is variance due to different reporting periods (1 April snapshot of ICRP versus full financial year reporting by DH). Secondly, the Department\'s National Institute for Health Research (NIHR) encompasses various expenditure on NHS infrastructure for research relevant to cancer that is not in a format that it is possible to capture for ICRP.
Macmillan (UK)	The ICRP database represents about 90% of Macmillan Cancer Support\'s direct research spend per financial year. There is some variance due to different reporting periods (1 April snapshot versus full financial year) meaning that some direct research spend that is planned for allocation will not be included in the ICRP figures. Expenditure on research management support and infrastructure to support Macmillan Cancer Support\'s activities is excluded from the NCRI, and by extension, the ICRP dataset.
Scottish Government Health Directorates (UK)	Scottish Government is committed to improve the health of the Scottish population and the Chief Scientist\'s Office (CSO) funds across a broad range of relevant disease areas. Overall, 75% of the CSO spend is committed to research infrastructure in NHSScotland. This and much other research expenditure is therefore outside the NCRI remit and, by extension, the ICRP dataset.

Canadian organizations who are part of the CCRA
Partner	Caveat
CCRA	Caveats/limitations specific to Canadian Cancer Research Alliance organizations can be accessed here.

Difference	Detail	Impact on investment figures
Not all CCRS participating organizations are included in the ICRP.	For the period 2005-2007, CCRA submitted data to the ICRP for 18 organizations and the three multi-funded initiatives (CBCRA, CPCRI, and CTCRI). This data represents ~30% of the investment documented/reported by the CCRS. We will address this issue, in part, with the 2008 data year submission as we will open data submission to all CCRS participating organizations.	Major for 2005-2007; medium impact expected from 2008 on.
Not all CCRS projects are (will be) included in the ICRP.	Even with all organizations included, some discrepancies will remain. Specifically, "related support" grants (i.e., travel awards, workshops/symposia, LOIs, etc.) and equipment/infrastructure grants that have a cancer relevance weighting of less than 100% are not reported to the ICRP, but are included in reports released by CCRA.	Medium overall; major impact expected for some organizations (e.g., CFI).
ICRP uses a different approach to calculating annual project investment.	CCRA provides ICRP with the full project amount and start and end dates. A pro-rated calculation is used to derive annual investment. CCRA bases its prorated calculations on annual project amounts (where those data are available) to account for differences in dollar flow.	Minor
ICRP uses different site coding conventions.	The cancer site/type codes used within the CCRS are different from ICRP site codes so results by site will vary in some instances.	Minor
ICRP has technical limitations.	ICRP has a technical limit of 12 site codes and 8 CSO codes and this requires truncation for a couple of large-scale projects within the CCRS.	Very minor
CCRA provides less descriptive information about its projects to ICRP.	Lay abstracts are submitted by CCRA to the ICRP in lieu of scientific abstracts and in their language of origin. For projects without lay abstracts (and there are a significant number of these), only titles are provided. An English translation is provided alongside all French project titles to facilitate use of the search engine.	No impact on investment figures, but limits full functionality of search engine especially for organizations that do not collect/report lay abstracts.